Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
10.3346/jkms.2013.28.7.1005
- Author:
Jae Heon JEONG
1
;
Byoung Chul CHO
;
Hyo Sup SHIM
;
Hye Ryun KIM
;
Sun Min LIM
;
Se Kyu KIM
;
Kyung Young CHUNG
;
S M Bakhtiar Ul ISLAM
;
Jae Jin SONG
;
Soo Youl KIM
;
Joo Hang KIM
Author Information
1. Yonsei University Graduate School of Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Transglutaminase 2;
NF-kappaB;
Lung Neoplasms
- MeSH:
Adenocarcinoma/*drug therapy/mortality/surgery;
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Agents/therapeutic use;
Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/surgery;
Disease-Free Survival;
Female;
GTP-Binding Proteins/*biosynthesis;
Humans;
Lung Neoplasms/*drug therapy/mortality/surgery;
Male;
Middle Aged;
NF-kappa B/biosynthesis;
Protein Kinase Inhibitors/therapeutic use;
Receptor, Epidermal Growth Factor/*antagonists & inhibitors/genetics;
Transglutaminases/*biosynthesis;
Treatment Outcome
- From:Journal of Korean Medical Science
2013;28(7):1005-1014
- CountryRepublic of Korea
- Language:English
-
Abstract:
Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-kappaB). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-kappaB expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-kappaB expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-kappaB value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinum-based doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P=0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P=0.013). Similarly, in EGFR wild-type patients treated with EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P=0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI.
